Dow Jones
38.852,27 +176,59 (+0,46%) Nasdaq
16.349,25 +192,92 (+1,19%) Nikkei 225
38.726,49 +490,42 (+1,28%) EUR/USD
1,0767 -0,0007 (-0,06%) Bitcoin EUR
59.043,99 -625,87 (-1,05%) CMC Crypto 200
1.362,35 +49,72 (+3,79%)
Celcuity Inc. (CELC)
Dopo ore:
| Chiusura precedente | 17,67 |
| Aperto | 17,85 |
| Denaro | 17,80 x 100 |
| Lettera | 17,88 x 200 |
| Min-Max giorno | 17,49 - 17,87 |
| Intervallo di 52 settimane | 8,39 - 22,19 |
| Volume | |
| Media Volume | 244.665 |
| Capitalizzazione | 543,283M |
| Beta (5 anni mensile) | 0,79 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,69 |
| Prossima data utili | 13 mag 2024 - 17 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 28,60 |
GlobeNewswireCelcuity to Host Virtual Science Day for Investors
Leading key opinion leaders to review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway in hormonally driven tumor typesDiscussion of the planned Phase 1b/2 trial for gedatolisib in combination with Nubeqa® (darolutamide) in patients with mCRPCEvent to be webcast from 10:00 a.m. – 12:00 p.m. ET on September 21, 2023 MINNEAPOLIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuin
- GlobeNewswire
Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial
MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into a clinical trial collaboration and supply agreement with Bayer AG for Celcuity’s Phase 1b/2 clinical trial of gedatolisib and Nubeqa® (darolutamide) in patients with metastatic castration resistant prostate cancer (mCRPC). As part of the supply agreement, Bayer will provide Nubeqa to C
- GlobeNewswire
Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer
- Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. – 12:00 p.m. ET MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) submission has been reviewed, and Celcuity can proceed
